Aligos Therapeutics, Inc. (ALGS): Nasdaq/NYSE listing notice — Aligos receives Nasdaq delisting notice for bid price below $1.00

Aligos Therapeutics, Inc.

Notice on Sep 5, 2023: stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sep 1.
Company has 180 calendar days, until Mar 4, 2024, to regain compliance by closing at $1.00 for 10 consecutive days.
If not cured, Aligos may be eligible for an additional 180-day period by transferring to Nasdaq Capital Market.
Company intends to monitor bid price and consider options, but compliance is not assured.
Potential delisting could occur if Staff determines cure is unlikely or other standards unmet.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Aligos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

rough September 1, 2023, the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). Nasdaq’s written notice does not result in the immediate delisting of the Common Stock from the Nasdaq Global Market In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has 180 calendar days, or until March 4, 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement.

View on SEC.gov

Browse all listing & compliance notices →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-230611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.